CA-TALKDESK
23.7.2020 16:02:07 CEST | Business Wire | Press release
Talkdesk®, Inc. , the cloud contact center for innovative enterprises, today announced $143 million in Series C funding from a combination of new and existing investors. The amount raised, and the company’s valuation of more than $3 billion, reflects both investor confidence in Talkdesk’s business and the strategic role that superior customer experience plays among top global brands.
New investors participating in this latest round include Franklin Templeton, Willoughby Capital, Skip Capital, Lead Edge Capital and Top Tier Capital Partners, along with existing partners Viking Global Investors and Threshold Ventures. In total, Talkdesk has raised $268 million over its funding rounds, strengthening its leadership position in the Contact Center as a Service (CCaaS) marketplace and solidifying the role of customer experience as a strategic differentiator for enterprises.
This latest investment follows a year of continued global growth, product development and market leadership for Talkdesk. Over the past 12 months Talkdesk has introduced more than 600 product innovations to the market including Talkdesk 20-in-20 , an ambitious release program to lead the contact center industry by starting 2020 with 20 product introductions in the first 20 weeks. Talkdesk’s culture of innovation led to 200 patent submissions in 100 days and continues to push customer service ahead with industry advancements like CXTalent and multiple awards .
The new funding will allow Talkdesk to capitalize on its current momentum and continue its global growth. The company plans to increase research and development spending and to invest in go-to-market, sales, marketing and channel development as Talkdesk continues to expand up-market.
Helping Brands Differentiate Through Customer Service During COVID-19
While companies have historically made significant investments in their contact centers as a means of differentiation through customer support, COVID-19 has served as a catalyst for accelerated investment in cloud-based solutions. Many consumer-facing brands have effectively lost their primary retail channel, making the need to provide world-class support a strategic imperative. As many enterprises move operations to a completely remote setting for the first time, Talkdesk’s cloud-native solutions ensure that agents can deliver an exceptional customer experience regardless of their location.
“The importance of providing an unparalleled customer experience has never been greater and this latest funding is a reflection of the criticality of this aspect as brands look for avenues for growth in our current environment,” said Tiago Paiva, chief executive officer, Talkdesk. “We are incredibly appreciative of the support and confidence of our investors, customers and partners who continue to endorse our vision of providing the industry’s most innovative and flexible solutions for the modern contact center. Lastly, I want to share my immense gratitude for the dedication and expertise of our employees who enable us to deliver for our customers, even during the most challenging times.”
"The global pandemic has fueled the importance of customer experience for business continuity. Talkdesk provides an innovative CX platform and solutions to help every organization provide the best possible and amazing customer experience,” said Mark Smith, chief executive officer and chief research officer, Ventana Research. “Our recognition of Talkdesk to receive the Ventana Research Digital Innovation Award in CX for 2020 is yet another example of the investment in innovation. The growth and funding is testament to the confidence and trust in the brand by customers and partners who have committed to Talkdesk."
The Talkdesk team consists of some of the world’s top authorities in the area of CCaaS and customer experience. The organization is a strategic and reliable provider to its customer base of more than 1,800 innovative customers in 75 countries including IBM, Acxiom, 2U, Trivago and Peloton.
Supporting Investor Quotes:
“We are excited to join Talkdesk in its journey to reimagine a critical element of business to consumer communications infrastructure, as businesses seek to enhance their relationships with customers with next generation digital engagement tools. Talkdesk’s market potential is large, and its business model is promising,” said Jonathan Curtis, vice president, research analyst and portfolio manager with Franklin Templeton’s Franklin Equity Group.
“We have been incredibly impressed by Talkdesk and the remarkable growth and scale the company has achieved over the last few years,” said Morgan Rutman, president, Willoughby Capital. “The company’s solutions are mission-critical across a range of industries during these challenging times. We are excited to support Tiago and the team through the next stage of the company’s evolution.”
"With a best-in-class product, Talkdesk’s rapid growth in the enterprise contact center segment is extremely impressive,” said Kim Jackson, founder, Skip Capital. “We are excited about accelerating cloud adoption, and as businesses of all sizes look for tools to help with a shift to remote work, Talkdesk’s product suite is highly compelling. We are thrilled to join the Talkdesk team on their journey."
"Talkdesk is a step above the outdated, legacy contact center systems and has quickly established itself as the vendor-of-choice. We're excited to partner with the company as its suite of products reaches an even greater scale," said Mitchell Green, managing partner, Lead Edge Capital. “Talkdesk is experiencing explosive adoption of its technology, and it is no surprise given the pain points its solving for companies, large and small.”
“Talkdesk is leveraging software and innovation to disrupt the traditional call center,” said Garth Timoll, managing director, Top Tier Capital Partners. “The company has emerged as a clear leader in the CCaaS sector and Top Tier Capital Partners is excited to support Talkdesk’s continued growth.”
"Threshold Ventures partners with exceptional entrepreneurs who have a vision for transformative, market-changing solutions. Tiago and the Talkdesk team are innovatively pushing CCaaS applications to a new level,” said Josh Stein, partner, Threshold Ventures. “Since leading their Series A financing, we’ve had a front row seat to watch Talkdesk emerge as an undisputed leader in the large CCaaS market."
Additional Resources:
- Hear direct from customers why they selected Talkdesk CX Cloud and the difference it has made in their contact centers
- Read more on how to boost support for your customers and employees when the unexpected happens
- Talkdesk 20-in-20 is revolutionizing contact center industry with 20 products in the first 20 weeks of 2020
-
Check out Talkdesk’s prestigious list of awards and recognition
, including recent recognition as a Leader in the 2019 Gartner CCaaS Magic Quadrant, North America
Tweet this : .@Talkdesk raises $143M in Series C funding. Valuation of $3B+ highlights the strategic role of superior customer experience among top global brands. https://bit.ly/3eUo5me
Social Networks:
- Web: https://www.talkdesk.com
- Blog: https://www.talkdesk.com/blog/
- Twitter: https://twitter.com/Talkdesk
- LinkedIn: https://www.linkedin.com/company/talkdesk/
- Facebook: https://www.facebook.com/Talkdesk/
- Instagram: https://www.instagram.com/Talkdesk/
About Talkdesk
Talkdesk® is the cloud contact center for the customer-obsessed. Combining enterprise performance with consumer simplicity, Talkdesk easily adapts to the evolving needs of support and sales teams and their end-customers, resulting in higher customer satisfaction, productivity and cost savings. Over 1,800 innovative companies around the world, including IBM, Acxiom, 2U, Trivago and Peloton, rely on Talkdesk to make customer experience their competitive advantage. Learn more and request a demo at www.talkdesk.com .
Talkdesk is a registered trademark of Talkdesk, Inc. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200723005079/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
